A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management

The 21-gene assay Oncotype DX (21-GA) shows promise as a guide in deciding when to initiate adjuvant chemotherapy in women with hormone receptor –positive early-stage breast cancer. Nevertheless, its routine use remains controversial, owing to insufficient evidence of its clinical utility and cost-effectiveness. Accordingly, we aim to quantify the value of conducting further research to reduce decision uncertainty in the use of the 21-GA.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research